Abstract: Adenosine was defined as a neuromodulator which exerts its action by interaction with specific Gprotein coupled receptor termed adenosine receptors. Adenosine receptors are expressed in several tissues and cells of our body and exist as four different subtypes of these receptors: A 1 , A 2A , A 2B and A 3 . In the last years significant efforts were made to obtain highly potent and selective ligands for the four adenosine receptors subtypes. Both agonists and antagonists were used as pharmacological tools to study therapeutic implications of enhancing or blocking the adenosine receptors activity, and some of these compounds have reached clinical phases. The pyrazolo [4,3-e][1,2,4]triazolo[1,5-c]pyrimidines (PTPs) represent one of the several templates designed as adenosine receptor antagonists. A lot of synthetic work was made on this scaffold in order to obtain potent A 2A and A 3 antagonists. Here were reviewed the synthetic approaches followed by both academia and industry to introduce different substituents at different positions of the PTP nucleus, in particular at the 2, 5, 7, 8 and 9 positions. Nevertheless PTP derivatives are tricyclic compounds with a high molecular weight which exhibit limitations such as poor aqueous solubility and difficult synthetic preparation. With the aim to obtain derivatives with the same potency and selectivity of PTP but with better drug-like properties, researchers made structural simplification of this scaffold. Replacement of the pyrazole or triazole rings of PTP led to the [1,2,4]triazolo[1,5-c]pyrimidine and pyrazolo [3,4-d]pyrimidine derivatives, respectively. Synthetic strategies for these compounds were reported, combined with the SAR profile on the adenosine receptors.
INTRODUCTION
Adenosine receptors (ARs) belong to class A of the G protein-coupled receptors family. A 1 , A 2A , A 2B and A 3 ARs are the four AR subtypes currently identified. [1] The endogenous agonist of these receptors is adenosine, whereas the natural psychotropic compound caffeine is a well-known exogenous AR antagonist. [1, 2] The different distribution of the four AR subtypes in cells, tissues and organs of the human body, confers to them different physio-pathological roles. [2] Potent and selective ligands (i.e. agonists and antagonists) at the various ARs are precious pharmacological tools, essential to characterize the ARs under physiological and pathological conditions. In the last decades, several AR antagonists have been reported and some of them were also tested in preclinical and clinical studies. [3] One of the most important class of AR antagonists are the pyrazolo [4,3-e] [1, 2, 4] triazolo [1,5-c] pyrimidines (PTP, 1a-b). PTP derivatives have been designed principally as A 2A and A 3 AR antagonists ( Figure 1 ). [4] Preladenant (SCH 420814, 2), an A 2A AR antagonist which possesses a PTP scaffold, has reached the phase III clinical trials for the treatment of Parkinson's disease (PD), but failed for lack of efficacy. [5] [6] [7] [8] In order to improve the pharmacokinetic properties of PTPs, a molecular simplification approach was applied on this complex tricyclic scaffold. The pyrazole ring of PTP was eliminated leading to the simplified [1, 2, 4] triazolo [1,5-c] pyrimidine (TP, 3) scaffold. [9] [10] [11] [12] [13] [14] Another nucleus which could be considered as a simplified analog, by removal of [1, 2, 4] triazole ring from PTP scaffold, is the pyrazolo [3,4-d] pyrimidine (PP, 4) nucleus. [15] [16] [17] [18] [19] [20] [21] Both of these classes of compounds led to derivatives that behave like adenosine receptor antagonists ( Figure 2 ). 
Adenosine receptors as drug targets
The adenosine receptors are involved in several physiological and pathological processes. [2] As GPCR (G protein-coupled receptor), A 1 and A 3 ARs are coupled with inhibitory G proteins (G i ), which inhibit adenylyl cyclase (AC) reducing the cyclic AMP (cAMP) levels. On the contrary, A 2A and A 2B ARs are coupled with stimulatory G proteins (G s ), those that activate AC enhancing the cAMP levels. Nevertheless, ARs were found to couple also to other G proteins, such as G q proteins for the A 2B and A 3 ARs, and G olf for the A 2A AR in the striatum. [1] In particular, activation of the A 1 AR could be useful for the treatment of cardiac arrhythmias and pain, whereas a block of the receptor activity is beneficial in hypertension, heart and kidney failure. Coronary artery vasodilation is mediated by A 2A AR, so agonists are useful as stress agents for myocardial perfusion imaging. Regadenoson is an A 2A AR agonist approved by Food and Drug Administration (FDA) for this use. [2] A 2A AR is also present in several immune cells and its activation leads to multiple anti-inflammatory effects. On the other hand, antagonists for the hA 2A AR were widely studied for the treatment of PD and other neurodegenerative disorders. [22] A 2B AR is activated by high levels of adenosine, which are usually reached under pathological conditions such as hypoxia and inflammation. [23] In fact, agonists for the A 2B AR are studied for the involvement in promoting ischemic preconditioning, whereas A 2B AR antagonists seems to be useful in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [24] Finally, regarding the last characterized among the ARs, the A 3 subtype, there are evidences of a cardioprotective effect mediated by A 3 AR agonists. Instead, for other physio-pathological conditions involving the A 3 AR (e.g. inflammation, cancer and glaucoma) conflicting results on a possible beneficial effect of agonists or antagonists have been obtained. [25] 
PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c] PYRIMIDINES
In 1993, Gatta et al. have reported the first pyrazolo [4,3-e] [1, 2, 4] triazolo [1,5-c] pyrimidine derivatives (1a-b) as A 2 adenosine receptor antagonists. [26] At that time, only few examples of non-xanthine heterocyclic compounds have been found to display antagonistic activity at the A 1 or A 2A ARs. Among these compounds CGS 15943 (5), a [1, 2, 4] triazolo [1,5-c] The pyrazolo [4,3-e] [1, 2, 4] triazolo [1,5-c] pyrimidine derivatives of this work displayed nanomolar affinity at the A 2A AR and represented a starting point for the development of a new class of potent and selective AR antagonists. [26] 
Chemistry
The original work by Gatta et al. [26] applied a synthetic approach, reported in Scheme 1, that started from 5-amino-N1-fluorobenzyl-1H-pyrazole-4-carbonitriles (7), which were obtained by reaction of 2-(ethoxymethylene)malononitrile (6) with 2-or 4-fluorobenzylhydrazine. [27] Compounds of general formula 7 were refluxed in triethylorthoformate to give the imidate derivatives (8) which, by reacting with benzhydrazide or 2-furoic acid hydrazide or ethylcarbazate, in ethylene glycol monomethylether at reflux, provided the corresponding 4-imino-4,5-dihydro-pyrazolo[3,4-d]pyrimidine derivatives (9, 11). The PTP nucleus was finally obtained by refluxing compounds of general formula 9 and 11 in diphenylether. The cyclization of derivatives 9 afforded the 7-substituted-3,7-dihydro-2H-pyrazolo [4,3-e] [1, 2, 4] triazolo [1,5-c] pyrimidin-2-one nucleus (10), whereas derivatives 11, which contain an additional aryl group, provided the pyrazolo [4,3-e] [1, 2, 4] triazolo [1,5-c] pyrimidine (12) nucleus substituted at both the 7 and the 2 positions. The following ring opening of the pyrimidine ring in compounds 12, by 10% hydrochloric acid, gave the (1H-1,2,4-triazol-5-yl)-1H-pyrazol-5-amines (13) . An alternative and more convenient route to obtain compounds with general formula 13 was the direct condensation of the appropriated arylhydrazides with the aminopyrazoles 7, in diphenylether at reflux. The triazolylpyrazoles 13 could be converted in 5-amino-7H-pyrazolo [4,3-e] [1, 2, 4] triazolo [1,5-c] pyrimidines (15) by reaction with cyanamide, or they could be alternatively converted to the 6,7-dihydro-5H-pyrazolo [4,3-e] [1, 2, 4] triazolo [1,5-c] pyrimidin-5-one (14) derivatives by reaction with ethyl carbamate. Finally, in order to obtain also the 8-substitued analogs, the appropriated starting compound N1-fluorobenzyl-3-amino-4-cianopyrazole (17) was obtained by alkylation of the 3-amino-4-cyanopyrazole (16) with the 2 or 4-fluorobenzylchloride in N,Ndimethylformamide (DMF) and using potassium carbonate as base. This approach led to a mixture 2:1 of alkylated pyrazoles 7 and 17. The desired compounds 17, separated by crystallization, were reacted with the corresponding aryl hydrazide (benzhydrazide or 2-furoic acid hydrazide) in diphenylether under reflux, affording the triazolyl derivatives 18. As for the previously reported compounds 13, also derivatives 18 were converted to the final tricyclic compounds (19) by reaction with cyanamide, in Nmethylpyrrolidone at 140-160°C and in the presence of ptoluensulfonic acid monohydrate. [26] With the aim to extensively explore the 7 position of the PTP scaffold, Baraldi et of unsubstituted (21) and N8-tert-butyl (22) derivatives (Scheme 2). [30, 5] As depicted in Scheme 2, the key intermediate 21 could be easily alkylated on the pyrazole nitrogen by using anhydrous potassium carbonate as base and dry DMF as solvent. The reaction proceeded without competition by the amino group at the 5 position of PTP, but it afforded two regioisomers, alkylated at the 7-(23) and 8-positions (24) of the PTP nucleus in a 3:1 ratio, respectively.
[28] The 7-and 8-alkylated PTP 23-24 were successively separated by column chromatography. This synthetic approach allows the introduction of different alkyl and arylalkyl moieties at the 7 and at the 8 positions, therefore both positions could be investigated at the same time. [28] Schering has developed a more convenient synthesis (Scheme 3) for the 2-aryl-7H-pyrazolo [4,3-e] [1, 2, 4] triazolo [1,5-c] -pyrimidin-5-ylamines (28) compared to the de-tert-butylation procedure (Scheme 2), which allows to obtain large amounts of key intermediate in three steps and requires soft purification procedures. [31] The synthesis started from the commercially available pyrimidine derivative 25, which may be obtained by Vilsmeier's reaction of 2-amino-4,6-dihydroxypyrimidine with POCl 3 and DMF. Compound 25 was reacted with aryl hydrazides affording compounds 26. A first cyclization was performed by treatment with hydrazine in acetonitrile, obtaining the pyrazolo [3,4-d] pyrimidines 27, then, a dehydrative cyclization of 27 with N,O-bis(trimethylsilyl)acetamide (BSA) at reflux proceeded with concomitant Dimroth rearrangement to afford the desired products 28. [31, 5] Additionally, pyazole alkylation, by using sodium hydride instead of potassium carbonate, afforded preferentially the N7-alkylated derivatives (29) with small amounts of N8-alkylated regioisomers.
In the same patent also other slightely different synthetic approaches were claimed. [31] As depicted in Scheme 4 the direct cyclization of compound 25 with hydrazine afforded the 4-chloro-1H-pyrazolo [3,4-d] pyrimidin-6-amine (30) , which could be in turn alkylated with the appropriated alkylhalide in the presence of NaH and DMF to obtain 31. As for the alkylation approach used in Scheme 3, also in this case, the use of NaH as the base led principally to N1-alkylated compounds, which correspond to the final N7-susbtituted PTPs. Subsequent reaction of compounds 31 with hydrazine and the appropriated acylchloride, or the direct reaction with the appropriated arylhydrazide, gave compounds of general formula 33. Finally, the dehydrative cyclization of compounds 33 afforded the desired N7-substituted-PTP derivatives (34) . When compound 30 was alkylated with 1-bromo-2-chloroethane, the obtained derivative 35 was reacted with tert-butylcarbazate, which afforded the 4-hydrazino derivative protected on the primary amino group by a Boc (tert-butyloxycarbonyl) moiety (36) . In this way, compound 36 could be further functionalized on the lateral chain at the N7 position (e.g. with 1-arylpiperarazines) (compound 37) and the subsequent deprotection of the amino moiety with HCl afforded compound 32 which then followed the above mentioned procedure.
All the synthetic pathways hitherto reported for the obtainment of 8-substituted-PTP required the separation of the two isomers of alkylated pyrazole derivatives. In fact, separation occurred at the early stage, such as for the original Gatta's procedure, or at a later stage, such as depicted in Schemes 2 and 3. In addition, a methyl moiety at the 8 position of the PTP scaffold was found to confer selectivity for the A 3 AR subtype. For these reasons, Pastorin et al. [32] decided to apply a well-known procedure for the regioselective preparation of the N1-methyl-3-amino-4-cyano-pyrazole (41) . [33, 34] Compound 41 was then used as starting material for the synthesis of the desired 8-methyl-PTP (42) which allows to easily explore the SAR of these derivatives. [33] The synthesis involved the formation of a hydrazone (39) between methylhydrazine (38) and benzaldehyde. This initial synthetic step allowed the protection of the non-alkylated nitrogen of methylhydrazine, thus directing the subsequent reaction with ethoxymethylene malondinitrile on the methylated nitrogen (compound 40). 1) , rt, 16h. R = arylalkyl, arylthioalkyl, aryloxyalkyl, (4-susbstituted-piperazin-1-yl)alkyl R 1 = Ar, phenyl, pyrrol-2-yl and their substituted derivatives, or nicotinoyl or cyclopent-1-en-1-yl, Ar = fur-2-yl, thien-2-yl.
The desired N1-methylpyrazole (41) was obtained by cyclization of compound 40 in a concentrated solution of hydrochloric acid and then converted to the 2-(furan-2-yl)-8-methyl-8H-pyrazolo [4,3- A detailed SAR analysis of the PTP nucleus at the ARs was obtained through investigations on the 5 position of the 8-substituted-PTP scaffold. [30, 32, [35] [36] [37] [38] [39] [40] [41] In particular, the treatment of the 5-amino derivatives (43) with various acylchlorides or isocyanates afforded the corresponding 5-amido (44) or 5-ureido (45) PTP compounds (Scheme 6). In the same conditions, the coupling reaction with isocyanates failed in the case of the 7-substituted-PTP pattern of substitution, probably due to the less nucleophilic character of the amino group at the 5 position. In fact, the nitrogen lone pair of the 5-amino group in 7-substituted derivatives is more extensively delocalized on the heterocyclic ring, than in the 8-substituted derivatives. [35] An alternative functionalization of the 5 position of PTP was obtained by conversion of the 6,7-dihydro-5H-pyrazolo [4,3- (48) , which could be easily reacted with different moieties containing an amino group. Federico et al. [42] reported a method to obtain compound 47 alternate to that of Gatta et al. and previously described by Francis et al. [44] for the triazoloquinazoline nucleus (Scheme 7). Following this method, the tricyclic urea 47 was prepared by reaction of the corresponding triazolylpyrazole (46) with diphosgene in dioxane at reflux. Then, the 5-chloro derivative was obtained by treatment of compound 47 with phosphorous oxychloride, phosphorous pentachloride and pyridine. The simple reaction of the 5-chloro derivative with three equivalents of the desired amino compound, in hot ethanol, gave a large series of 5-aminosubstituted-PTP derivatives (49) . [42] [43] [1, 2, 4] triazolo [1,5-c] pyrimidine (19) . The most promising compounds at the A 2A AR were found among the 5-aminopyrazolo [4,3- [26, 29] These compounds (52,53) bear a free amino group at the 5 position, a 4-fluorobenzyl moiety at the 7 or 8 positions and a 2-furyl ring at the 2 position (Figure 4 ). Further investigations were performed on the pyrazole substitution, maintaining the optimal NH 2 and 2-furyl groups at the 5 and 2 positions, respectively. PTP was substituted on the pyrazole ring, at the 7 and 8 positions, with alkyl or aralkyl moieties, confirming that the 7 substitution improved selectivity at the A 2A AR, as clearly demonstrated by comparing compound 54 ( Figure 4 ) with its corresponding 8-β-phenylethyl derivative, which were 52.6 and 3.4 fold selective for the rA 2A vs rA 1 ARs compound, respectively. In addition, among 7 substitutions, arylalkyl moieties (e.g. 7-(3-phenyl)propyl, compound 55, SCH63390) were found to confer higher selectivity at the A 2A AR than alkyl moieties (e.g. 7-n-butyl, compound 56). [29, 47] Compound 54, named SCH58261, was synthesized also in its triatiated form, [ 3 H]SCH58261, which demonstrated to label A 2A receptors with high affinity (K D = 0.7 nM) and high specific binding (> 90%). [48] Furthermore, SCH58261 (54) maintained antagonism at the A 2A AR in in vivo cardiovascular models and behave as a central nervous system stimulant, like caffeine. [29] Nevertheless, compounds 52-56 are highly lipophilic compounds presenting poor solubility in water. In order to enhance the hydrophilic character of PTP derivatives, while retaining high affinity and selectivity at the hA 2A AR, several polar moieties have been introduced on the aryl group of the substituent at the 7 position. [49, 50] All the synthesized compounds showed a good affinity and selectivity for hA 2A AR with different degrees of selectivity over the hA 1 AR. On the other hand, all compounds were inactive at the hA 2B and hA 3 ARs. As previously demonstrated, the best length for the side chain is three methylene groups between 7 and the aryl moiety. In fact, promising results were obtained introducing a hydroxyl group at the para position of the phenyl ring of SCH63390 (55) Interestingly, SCH63390 (55) was conjugated with a fluorescent moiety, Alexa-Fluor 488, by a N-(2-aminoethyl)amido linker, affording MRS5346 (61) which was used in A 2A adenosine receptor fluorescent polarization assays in place of traditional radioligand based binding studies. MRS5346 (61) possessed a K i affinity value of 111 nM at the hA 2A AR, but it was inactive at the other AR subtypes at 10 μM concentration. [52, 53] Because the goal to achieve water solubility by introducing polar group on the phenyl ring of 7-arylalkyl-PTP failed, an additional piperazine ring was introduced as a spacer between the aryl and the alkyl moieties at the 7 position. The aryl ring consists in a phenyl ring variously substituted, in particular at the para position. All the developed compounds displayed affinities in the low nanomolar range and retained selectivity over A 1 AR ( Figure  5 ). [5] Considering that compounds were developed as promising therapeutic agents in PD, they were orally employed in the rat haloperidol-induced catalepsy model. The first compound to be tested was the unsubstituted phenyl derivative (62) , which exhibited a good oral activity at 1h post-dose, but became inactive after 4 h. Inactivation is due to metabolic conversion to the para-hydroxyl derivative (63) which, despite its high affinity at the A 2A AR (hA 2A AR K i = 1.3 nM), shows inactivity at an oral dose of 1 mg/Kg. For these reasons, several derivatives bearing substituted phenyl moieties, able to extend the duration of action, were developed. Among them, 2,4-difluorophenyl derivative (SCH412348, 64) displayed potent oral activity, but its solubility remained poor. The strategy to improve water solubility of those compounds was to introduce ether-linked substituents. Also in this case, all the derivatives showed nanomolar or subnanomolar affinities at the hA 2A AR. The most interesting compound was the 4-methoxyethoxy derivative (2), named SCH420814, which exhibited a robust oral anti-cataleptic activity and a solubility in water, as the crystalline free base, of 0.2 µM at native pH (5.1), and 2 mM in 0.01 N HCl. [5] SCH420814 (2) was subjected to extensive profiling, reaching also clinical trials under the name of Preladenant (see Section 2.3). [6] [7] [8] A 3 
AR antagonists
The rationale for the development of PTP derivatives as A 3 AR antagonists consists in hybridization between the PTP core, known to behave as antagonist at the A 2A ARs, and the arylcarbamoyl moiety of potent rA 3 AR agonists (such as compound 65 in Figure 6 ), which were known to confer affinity for the rA 3 AR subtype. [54, 35] Since the coupling reaction with isocyanates was successful using 8 alkylated compounds, but it failed in the case of the 7 pattern of substitution (see Section 2.1 Chemistry), only 8-substituted derivatives were developed.
All the synthesized compounds showed high affinity at the hA 3 AR (e.g. nanomolar or subnanomolar affinities), with different degrees of selectivity depending on both arylureido and (ar)alkyl substitutions present at the 5 and 8 positions, respectively. Also compounds lacking the phenylcarbamoyl moiety at the N5 position were assayed at the various AR [30, 35] An in-depth investigation on the 8 position, by introducing various alkyl and arylalkyl moieties, revealed that small alkyl groups, such as methyl, were the optimal substituents, conferring high affinity at the A 3 AR subtype and good selectivity over the other AR subtypes (i.e. compound 68, hA 3 AR K i = 0.20 nM; A 1 /A 3 = 5,485; A 2A /A 3 = 6,950). [30] Starting from the 8-allyl compound 69, [30] it was possible to obtain the corresponding tritiated derivative, which bears a 8-propyl group, named [ 3 H]-MRE-3008-F20 (70), the first selective radioligand for the hA 3 AR behaving as antagonist. [55, 56] Later, also the N5 position was deeply investigated. First of all, different substituents (e.g. chloro, fluoro, bromo, methyl, methoxy, nitro, sulfonic acid, trifluoromethyl) have been introduced at the ortho, meta and para positions of the phenyl ring of the 5-phenylureido group, while maintaining a small alkyl group at the 8 position. Curiously, all the compounds affinity values at A 3 AR were in the range 0.16-3.7 nM, except for derivatives bearing a para-sulfonic acid group which dispayed a K i value above 25 nM (i.e. compound 71), indicating that para-substituent is surrounded by a lipophilic environment inside the A 3 AR binding cleft. Molecular modeling studies on the hA 3 AR suggested that a steric control is present at the para and, especially, at the meta positions of the phenyl ring. [36] One of the most potent and selective compounds of this series was the unsubstituted compound 72, which showed a K i of 0.16 nM at A 3 AR and > 2000-fold selectivity for A 3 over A 1 and A 2A ARs. The replacement of phenylureido moiety with a phenylacetyl moiety, maintained affinity at the hA 3 AR, while a slight decreased selectivity was observed (compound 72 vs compound 73 in Figure 6 ). [36] Instead, the introduction of a shorter amide, such as the benzamide (compound 74) had a detrimental effect on affinity at the A 3 AR (i.e. compound 74, hA 3 AR K i = 15.7 nM). [57] In order to achieve water solubility of these lipophilic compounds, and taking in account the steric control which is present around para position, the phenyl ring at the 5 position was replaced with a pyridine ring. In addition, the position and the basicity of pyridine nitrogen were evaluated. [32, 37] The most potent compound of the series, which was also the most potent A 3 AR antagonist ever reported (compound 75), bears the 4-pyridinium moiety as hydrochloride salt. (Figure 7 ) Moreover, as all the PTP derivatives, also compound 75 proved to be inactive in rats. 1 μM concentration of compound 75 displaced only 35% of the binding of a specific radioligand at rA 3 receptors. [32, 37] The 4-pyridylcarbamoyl moiety conferred good water solubility at low pH (<4.0) but poor solubility at physiologic pH. Thus, the replacement of pyridin-4-yl moiety with a 1-(substituted)piperidin-4-yl ring was performed to exploit the higher basicity of this nucleus and the possibility to generate stable, water-soluble salts. The hydrochloride salt of the 1-(cyclohexylmethyl)piperidin-4-yl derivative (76, hA 3 AR K i = 9.7 nM; A 1 /A 3 = 351; A 2A /A 3 > 515) showed a solubility of 8 mg/mL at physiological pH and gave a stable aqueous system suitable for intravenous infusion. [41] More recently, an extensive exploration of a large variety of polyfunctionalized chains (i.e. alkylamino, arylalkylamino, heterocyclic moieties) at the 5-position has been reported. Almost all the synthesized compounds showed affinity for the hA 3 AR in the nanomolar or subnanomolar range, with different levels of selectivity over the other AR subtypes. 
4). [42]
Substitution at position 2 of the PTP tricyclic system has not been deeply explored, being essentially limited to the introduction of a furyl group. Baraldi et al. have found that the substitution of the furan ring with phenyl or substitutedphenyl and furyl rings led to a loss of affinity at all the AR subtypes. Remarkably, substitution at the pyrazole ring of PTP nucleus occurred at the 7 rather than at the 8 position. [58] In addition, several reported tricyclic hA 3 AR antagonists bear a substituted phenyl moiety at the position equivalent to that of furan ring in PTP derivatives. [59] For these reasons, Cheong and coll. [39] designed and synthesized a series of PTP bearing a (para-substituted)-phenyl ring at the 2 position, while maintaining either methyl or phenyl-ethyl groups at 8 position and a free amine, phenylacetamide or (bis-)benzamide at the 5 position.
Interestingly, 5-amino derivatives were unselective AR antagonists (i.e. compound 79), whereas the 5-phenylacetamido derivatives retained high affinity at the hA 3 AR and showed a remarkably improved selectivity profile toward the other AR subtypes in comparison to the 2-furyl PTP derivatives (e.g. compound 80, hA 3 with no substitution (e.g. compound 81 (4-F-Ph), hA 3 AR K i = 1.9 nM; A 1 /A 3 = 321; A 2A /A 3 > 5,263 vs compound 82 (Ph), hA 3 AR K i = 2.1 nM; A 1 /A 3 = 12.9; A 2A /A 3 = 90.5). [46] Finally, also the 9 position was examined by Baraldi et al. by introducing substituents with different steric and hydrophilic/lipophilic features, such as: alkylamino, arylamino, alkylthio or N-methylpiperazino moieties. These compounds maintained the classical methyl group at the 8 position and the free amino, phenylureido or arylacetamido moieties at the 5 position of the PTP nucleus. [57] Notably, the introduction of a substituent at the 9 position led to a complete loss of selectivity, even if affinity at the ARs in the nanomolar range was maintained. Generally, the methylthio group at the 9 position was the best tolerated, such as in compound 83, which exhibited K i values lower than 35 nM at the four AR subtypes. [58] Antagonists for other AR subtypes Although a clear SAR profile for the PTP derivatives have been outlined at the A 2A and A 3 ARs, a similar correlation at the A 1 and A 2B ARs is still lacking (Figure 8 ). Concerning both A 1 and A 2B AR subtypes, potency was achieved but selectivity was very poor. Nevertheless, some common features could be observed in the potent, even if not selective, PTP A 2B antagonists. In fact, substitution at the 8 position was preferred to that at the 7 position for binding at the A 2B AR; moreover, arylalkyl or branched alkyl moieties were preferred to small alkyl moieties. Compounds 66 ( Figure 6 ) and 84 ( Figure 9 ), bearing a phenylethyl and isopentyl groups at the 8 position, respectively, showed affinity in the nanomolar range at the A 2B AR (e.g. 66, hA 2B AR K i = 5.1 nM; 84, hA 2B AR K i = 9.1 nM). [30] A slight improvement of selectivity towards A 2A AR was achieved by introducing a γ-aminobutyrylamido or a phenylacetamido group at the 5 position of the PTP nucleus (compounds 85 and 86), but unfortunately a simultaneous loss of selectivity over the A 1 and A 3 ARs was observed. [30, 60] Even regarding the A 1 AR subtype, 8-substituted-PTPs showed improved affinity if compared to the 7-substituted derivatives: see compounds 53 and 54 ( Figure 4 ) versus compounds 52 and 66 (Figures 4,6 ), which bear an arylalkyl group at the 7 and 8 position, respectively. [30] In addition, substitution on the amino group at the 5 position of 8-substitued PTP derivatives seemed to have a detrimental effect in terms of affinity at the A 1 AR. In fact, compound 86 ( Figure 9 ), which is the 5-phenylacetyl derivative of compound 66, displayed a 120-fold detrimental effect on affinity value at the hA 1 AR (86, hA 1 AR K i = 120 nM; 66, hA 1 AR K i = 1 nM). [30, 38] of dopamine D 2 receptors on GABAergic striatopallidal neurons. In fact, A 2A ARs and D 2 receptors have also been found to form heteromers. These findings raised the possibility to use A 2A AR antagonists to reduce the postsynaptic effects of dopamine depletion, and in turn diminish the motor deficits of PD. [61, 62] Schering-Plough Research Institute, starting from the observation that SCH58261 (54) is a promising A 2A AR antagonist with a PTP scaffold, has developed a new series of derivatives with the aim to simultaneously enhance selectivity among the other ARs and improve pharmacokinetic properties of the PTP compounds. A variety of 7-alkylated PTPs were prepared, in particular, 7-(4-arylpiperazin-1-yl)ethyl derivatives were of particular interest. Almost all the synthesized derivatives showed high A 2A AR binding affinity, with high selectivity over A 1 AR. Further efforts were directed toward improving solubility by introducing ether-linked substituents at the para position of the aryl moiety; these compounds maintained high affinity and selectivity at the hA 2A AR. The most promising compound resulted to be SCH420814 (2), then named Preladenant (2). [5] Preladenant (2), whose synthesis is reported in Scheme 9, it is prepared by alkylation of compound 21 (obtained as shown in Scheme 3) with ethylene glycol ditosylate, which afforded the desired tosylate derivative 87 as the major product, along with minor amounts of the 8-alkylated compound. Amination of compound 87 with the N-arylpiperazine 88 in DMF at 80 °C afforded Preladenant (2) in good yields. The necessary N 1 -(4-(2-methoxyethoxy)phenyl)piperazine (88) is obtained by reacting the 1-acetyl-4-(4-hydroxyphenyl)piperazine (90) with sodium hydride in DMF and then adding the 2-bromoethylmethylether. [31] In a preliminary profiling, Preladenant (2) exhibited high affinity for both human and rat A 2A ARs, with K i values of 1.1 and 2.5 nM, respectively. In addition, the compound was more than 1000-fold selective for hA 2A ARs over hA 1 , hA 2B and hA 3 ARs. In cell-based assays, Preladenant (2) blocked adenylate cyclase activity stimulated by the A 2A AR agonist CGS21680 with K b values of 0.7 nM (rat) and 1.3 nM (human), confirming that it is an antagonist. The compound did not show significant binding at a concentration of 10 μM against a panel of 60 other receptors, ion channels and transporters. In vivo, SCH420814 dose-dependently reversed haloperidol-induced catalepsy (haloperidol is a D 2 receptor antagonist) in the rat and in the squirrel monkeys. The solubility of Preladenant (2) as crystalline free base in water is 0.2 μM at native pH (5.1) and 2 mM in 0.01 N HCl. [5] One of the drawbacks of current dopamine replacement therapies for PD is the development of dyskinesias after chronic activation of D 2 receptors, which correlates with an increased number of A 2A ARs. Therefore, treatment with an A 2A AR antagonist, by blocking the upregulated A 2A AR and avoiding the direct activation of D 2 receptors, may ameliorate PD symptoms while reducing the risk of developing dyskinesias. In rodent models of PD, Preladenant (2) demonstrated to be efficacious without leading dyskinesias both as monotherapy or coupled with L-Dopa. In addition, PD patients often suffer depression and Preladenant (2) gave positive results in the FST (forced swim test) and TST (tail suspension test) models of behavioral despair, suggesting the potential use of A 2A AR antagonists in the treatment of also non-motor PD symptoms. Supported by all these results, Preladenant (2) has become an excellent candidate for clinical studies on the treatment of both the motor and non-motor symptoms of PD. [6] In a phase I study, the safety, tolerability and pharmacokinetics of Preladenant (2) at single and multiple oral doses were evaluated. Preladenant (2) was generally tolerated up to 200 mg/day after oral administration of both single dose and multiple doses for 10 consecutive days. Preladenant (2) reached peak plasma concentrations in about 1 h and then declined rapidly; the effective half-life was about 8 h. [63] A phase II study displayed that 5 and 10 mg Preladenant (2) twice daily might be clinically useful to reduce off time in Parkinsonian patients with motor fluctuations who are receiving levodopa and other antiparkinsonian drugs (1 and 2 mg of Preladenant (2) are Scheme 9. Reagents: i: ethylene glycol ditosylate, NaH, DMF, N 2 , rt, 24h; ii: compound 88 DMF, 80°C, 20h; iii: NaH, DMF, CH 3 OCH 2 CH 2 Br, rt, 18h, followed by HCl 6N, rfx, 1h. ineffective). Mild transient increases in blood pressure were observed and these are consistent with the expected biological effects of A 2A AR inhibition. [64] These results were confirmed by a second phase II study, which evaluated the long-term safety and efficacy of Preladenant (2) . [65] Preladenant (2) was prepared also in its radiolabeled form 14 C-preladenant (Preladenant (2) was labeled at the carbon at position 2) and orally administered in human healthy subjects in order to study its metabolism and excretion. The identified metabolites of Preladenant have been depicted in Figure 10 and principally consist of O-demethylation and subsequent oxidation, N-dealkylation and furan ring opening. After a single administration of Preladenant (2), the dose was principally eliminated in feces (>65%) while a minor part of the dose was eliminated in urine (<10%). In plasma were identified both Preladenant (2) and its metabolites 92 and 93. In the feces, the 14% of the dose is the unaltered drug, while the major metabolites are compounds 92 (29%), 91 (22%) and 90 (6%). In urine Preladenant (2) was not detected and the most prevalent metabolite is compound 92 (3.53%). Among the identified metabolites, compounds 92-94 retain high affinity at the hA 2A AR. [66] Unfortunately, phase III clinical trials of both adjunctive and monotherapy with Preladenant (2) in patients with PD, failed to prove drug efficacy. Nevertheless, trials were also unable to identify benefit for rasagiline, the active control; therefore it is difficult to interpret these results and what they mean for Preladenant (2) in early Parkinson's disease. [7, 8] The [1, 2, 4] triazolo [1,5-c] pyrimidine (TP) is a versatile scaffold, which has been reported to bind different protein targets depending on the pattern of substitutions present on its structure, [67, 70] including adenosine receptors [9] [10] [11] [12] [13] [14] . In fact, TP nucleus (3) is a clearly structural simplification of the PTP scaffold (1), in which pyrazole ring has been removed. (Figure 11 ) Here are reviewed chemistry and SAR profile relative to TP derivatives developed as AR antagonists.
Preladenant: a case study
Preladenant (SCH420814, 2), 2-(furan-2-yl)-7-(2-(4-(4- (2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H- pyrazolo[4,3-e][1
Chemistry
Kyowa Hakko Kogyo Co. was the first company to develop TP derivatives for their use as A 2A AR antagonists. [9] The Japanese company deeply explored the chemistry of TP compounds as evidently shown in Schemes 10-12. Several alternative approaches could be used to prepare the TP compounds; in particular, modifications in the series of the reaction steps allow to introduce the desired substituents on the TP nucleus. The starting material could be a compound of general structure 96 (Scheme 10). 4,6-dichloro-2-(methylthio)pyrimidine but also some 4,6-dichloro-5-substituted-2-(methylthio)pyrimidines are commercially available or easily achievable by synthesis. One synthetic approach considered the consecutive substitution of the two chlorine atoms on the pyrimidine ring (96): the first with nucleophilic compounds such as amines, alcohols and thiols, obtaining compound 97, and then the second with the appropriated aryl hydrazide, which afforded compound 98. These two steps could be inverted (103, 98) and, in both cases, the first substitution was made at room temperature in the presence of a base, whereas the second required heating. The hydrazido derivative 98 underwent dehydrative cyclization with phosphorous pentoxide and hexamethyldisiloxane (HMDSO), which formed the dehydrating agent polyphosphoric acid trimethylsilyl ester (PPSE), in xylene. TP derivative 99 was obtained by Dimroth rearrangement of [1, 2, 4] triazolo [4,3-c] pyrimidine derivative 100, which generally occurred during the reaction.
In some cases, only compound 99 were isolated, indicating that rearrangement was favored. Compound 99 were reacted with veratrylamine in DMSO (dimethylsulfoxide) at 140°C to afford compound 101, which is a 5-amino-TP derivative protected on the amino group with veratryl moiety. Also this reaction facilitates Dimroth rearrangement, so reaction could also be made on the unpurified mix of compounds 99 and 100. Deprotection of amino group at the 5 position of compound 101 was obtained by treatment with trifluoroacetic acid (TFA), triflic acid and anisole. This last step led to the desired 5-amino-7,8-disubstituted-TPs (102). Alternatively, a chlorine atom of the starting pyrimidine derivative (96) could be maintained during all the synthesis, following the same reactions depicted above with slight modifications. Scheme 11. Reagents: i: RB(OH) 2 , (PPh 3 ) 2 PdCl 2 , Na 2 CO 3 , THF, rfx, 9h, or (n-But) 3 This approach allows access to larger quantities of precursor (107) which could be then substituted with the desired substituents at the 7 position. Furthermore, the chlorine atom may be substituted after cyclization step, leading to The Stille reaction between compound 109 and tert-butyldimethyl-(tributylstannylmethoxy)silane, followed by deprotection of hydroxy group, afforded the 7-hydroxymethyl-TP (111). The 7-aldehyde derivative (113) was obtained by deprotection of the amino group at the 5 position and oxidation of the hydroxy moiety at the 7 position of compound 111. Further oxidation of compound 113 afforded the corresponding carboxylic acid (114), which may be treated with coupling reagents for the synthesis of amides.
On the other hand, reductive amination of compound 113 with the desired amine and sodium triacetoxyborohydride led to 7-(substitutedamino)methyl-TP derivatives (115). Finally, the hydroxyl group of compound 111 may be converted by Mitsonobu recation in the corresponding arylether derivatives (112). The last example of different substitutions that can be applied at the 7 position of the 7-chloro-TP derivative (109) involved its reaction with bis(tributyltin) in order to obtain the corresponding organotin derivative (116). Compound 116 is a substrate for Stille reaction and, in fact, the treatment with acylchlorides gave ketone derivatives of general formula 117. [72] Instead, TP derivatives bearing different substituents at the 8 position have been obtained using the ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (118) as starting material. Compound 118 is commercially available but it is easily synthesized by condensation between isothiourea and diethyl ethoxymethylene malonate in basic condition, which led to a pyrimidine sodium salt that after treatment with phosphorous oxychloride afforded compound 118. [73] As displayed in Scheme 12, pyrimidine derivative 118 was converted in the Compound 121 may be deprotected on the amino group to afford compound 128 or modified at the 8 position and subsequently deprotected to afford the final desired compounds. Hydrolysis in basic conditions of the ethyl ester group of compound 121 led to the carboxylic derivative 124, which was converted to the amido derivatives (126) by reaction with mono-or di-substituted amines in the presence of thionyl chloride in pyridine. Instead, the coupling reaction of compound 124 with N,O-dimethylhydroxylamine, carried out by the use of EDCI and HOBt as coupling reagents, afforded the Weinreb-Nahm amide 125. The treatment of compound 125 with a Grignard reagent led to the corresponding ketone derivative (122). When R 1 in compound 122 in Scheme 12 is an ethyl, the Weinreb-Nahm ketone synthesis was performed by one-pot reaction directly from the ethyl ester derivative (121). Alternatively, compound 121 was reduced to 8-hydroxymethyl (129) derivative by diisobutylaluminum hydride, which was in turn oxidized with manganese dioxide to obtain the 8-formyl derivative (130), analogously to that reported in Scheme 11 for compound 111 (to obtain compound 113). By reductive amination of compound 130, aminomethyl derivatives 132 Scheme 13. Reagents: i: RR 1 NH, EtOH, sealed tube, 120°C, 2h; ii: NH 3 7N/MeOH, EtOH, sealed tube, 120°C, 2h; iii: R 4 NCO, dry THF, rfx, overnight, or R 4 CH 2 COCl, dry THF, TEA, rfx, overnight. R,R 1 ,R 2 ,R 3 = alkyl, arylakyl or RR 1 NH are saturated heterocycles with at least one nitrogen as heteroatom. R 4 X = PhCH 2 , PhNH, c-C 6 H 11 -NH. have been obtained, whereas the Grignard reaction led to the secondary alcohols of general formula 134. Compounds 134 were oxidized by pyridinium chlorochromate to afford again ketones with general formula 122. [9, 71] Recently, our group developed 5,8-disubstituted-TPs based on the Kyowa Hakko Kogyo Co. procedure displayed in Scheme 12 (Scheme 13). Procedure was slightly modified in order to introduce different substituents at the 5 position. [14] In fact, compound 120, which was obtained as in Scheme 12, was reacted with different amines in hot ethanol to afford different 5-amino derivatives (135) in good yields. By using ammonia, compound 128 has been directly obtained. Compound 128 or compounds of general formula 127 (obtained as depicted in Scheme 12) were treated with appropriated isocyanates or acylchlorides in order to achieve the corresponding 5-ureido and 5-amido derivatives (136). [14] Schering developed a large series of TP compounds, mainly applying a chemistry similar to those applied by Kyowa Hakko Kogyo Co. As shown in Scheme 14, Schering approach uses directly the 2-amino-4,6-dichloro-pyrimidine (137) as starting material. As reported by Kyowa Hakko Kogyo Co., a first chlorine atom was substituted with amines, alcohols, or thiols to give compounds of general formula 138. In this step, different reagents were employed on the basis of the nucleophile used (i.e. potassium carbonate for amines, sodium hydride for alcohols and sodium sulfide with aryl or alkylchlorides for thiols).
Alternatively, compound 137 may be coupled with alkyl or arylalkyl moieties by Suzuki coupling affording compounds of general formula 144. Compounds 138, 144 or the unsubstituted derivative 137 were reacted with the desired arylhydrazide in acidic (138) or basic conditions (137, 144) and derivatives 139, 145 and 141 have been obtained. Compounds 139, 141 and 145 were then cyclized in dehydrating conditions to the 5-amino-TPs (140, 142, 143 ). Schering applied similar cyclization conditions to that used to prepare PTP derivatives, which are BSA at 120°C for 18h. An alternative synthetic route was used to introduce different aryl moieties at the 2 position of the TP nucleus, which involved the reaction between compound 138 and tertbutylcarbazate, in solution containing HCl, to form the NBoc-hydrazine derivative 146. After removal of the Boc protecting group, the resulting 6-hydrazinyl-pyrimidines (147) were coupled with the desired carboxylic acid by using EDCI, HOBt and NMM, thus leading again to compounds of Scheme 14. Reagents: i: a) for X = N, RR 1 NH, K 2 CO 3 , EtOH, sealed tube, 90°C, 1h, b) for X = O, ROH, NaH, THF, rfx, 24h, c) for X = S, Na 2 S, DMF, RCl, 80°C, 18h; ii: aryl hydrazide, 1N HCl, EtOH, sealed tube, 90°C, 16h; iii: BSA, 120°C, 18h; iv: aryl hydrazide, K 2 CO 3 , EtOH, sealed tube, 100°C, 18h or aryl hydrazide, BuOH, 90°C, 20h; v: for X = N, RR 1 Schering has reported an alternative method to synthetize 7 and 8 aryl or arylalkyl substituted TP derivatives, as shown in Scheme 15. The desired 2-amino-4-chloro-5,6-disubstituted-pyrimidines (152) were obtained from condensation between guanidine carbonate and the corresponding β-ketoesters 150, followed by treatment with phosphorous oxychloride which introduced a chlorine atom in place of hydroxy group of compounds 151 at the 4 position. The desired β-ketoesters 150 can be obtained both by alkylation of a β-ketoesters of general formula 148 and by reaction of ketone derivatives 149 with ethylchloroformate. The pyrimidines 152 were converted to the final desired compounds 154 following the same procedures reported in Scheme 13 with slight modifications. [13, [74] [75] Finally, 5-amino-2-(furan-2-yl)- [1, 2, 4] triazolo [1,5-c] pyrimidin-7-ol (157) was obtained from 2-amino-6-chloropyrimidin-4-ol (155), as shown in Scheme 16. The hydroxyl moiety of compound 157 was treated with triflic anhydride to give compound 158, which bears the triflate group, a pseudohalide moiety useful for the subsequent Stille cross-coupling reaction. Thus, this reaction represents another way to obtain 5-amino-7-aryl-2-furyl-TP derivatives (159). [75] Biogen Idec also investigated the TP scaffold for searching A 2A AR antagonists. The company applied a strategy very similar to those reported above. In fact, as shown in Scheme 17, they used the 7-chloro-2-(furan-2-yl)- [1, 2, 4] triazolo [1,5-c] pyrimidin-5-amine (160) to introduce different moieties at the 7 position. The 7-susbtituted-amino derivatives (161) were obtained as reported above but using cesium fluoride as base. Instead, compound 160, by Sonogashira cross-coupling reaction with 1-substitited-4-(prop-2-yn-1-yl)piperazine, followed by a catalytic hydrogenation, afforded 7-(4-substitited-piperazin-1-yl)propyl-TP derivatives (163). [76] [77] [78] 
Structure activity relationship
TP derivatives were almost exclusively reported in patents. In patents, binding data are often incomplete and this makes it difficult to assess the SAR profile of these compounds. All the patents on TP derivatives target A 2A AR. Kyowa Hakko Kogyo Co. developed a series of TP mainly maintaining the furyl group at the 2 position and the free amino group at the 5 position of TP scaffold, because these substitutions were known to confer high affinity at the A 2A AR subtype in the PTP series (see Section 2.2). The introduction of both phenoxy (164) and benzylthio (165) moieties led to potent A 2A AR antagonists (164, hA 2A AR displ. at 0.1 µM = 89%; 165, hA 2A AR displ. at 0.1 µM = 82%). Unfortunately, selectivity profile among ARs have not been reported for these compounds. [71] (Figure 12 ) Neustadt et al. developed a series of TPs bearing aryloxy, arylthio and arylamino moieties at the 7 position. They confirmed that all these substitutions led to potent A 2A AR antagonists, but only derivatives bearing an additional small alkyl group on the nitrogen at the 7 position displayed good selectivity over the hA 1 AR (i.e. compound 166). [13] Nevertheless, the most investigated substitution on the TP scaffold has been the piperazino group. Kyowa Hakko Kogyo Co. found that introduction of N-alkyl-, Nhydroxyalkyl-or N-aryl-piperazines at the 7 position of the TP nucleus led to derivatives that displayed poor affinity at the A 2A AR (e.g. compound 167, hA 2A AR displ. at 0.1 µM = 42%; compund 168, hA 2A AR displ. at 0.1 µM = 36%). [71] Instead, N-arylalkyl-piperazines, with alkyl linkers ranging from 1 to 3 methylene groups (i.e. compound 169), increased affinity at the A 2A AR. Compound 169 was demonstrated to be effective in a MPTP model of PD. [71] Furthermore, piperazine could also be replaced with a piperidine or a 1,2,3,6-tetrahydropyridine, such as in compound 171, which showed high affinity at the A 2A AR. [72] As an extension of the series of piperazine derivatives of [1, 2, 4] triazolo [1,5-c] pyrimidines, Biogen Idec. explored the possibility to introduce a flexible alkyl spacer between the TP nucleus and the piperazine moiety. Compounds 172, 173 and 174 clearly showed that an aminoethyl spacer gave quite potent and selective A 2A AR antagonists (172), however methylation at the amino group improved both affinity and selectivity at the A 2A AR (compound 173). Finally, substitution of the amino group with a methylene group had a detrimental effect on affinity at the A 2A AR (compound 174). [76] ScheringPlough Research Institute developed a large series of piperazine and piperidine derivatives using a phenyl ring as a linker between the TP nucleus and the heterocyclic group. Initially, a series of different 7-aryl compounds have been synthesized, demonstrating that an aryl group is well tolerated at the A 2A AR, with affinity values in the nanomolar range. Interestingly, compound 175 showed a high affinity at the A 2A AR with a good selectivity over the (2), seemed particularly beneficial in terms of selectivity over A 1 . In fact, compound 176, which displayed K i values of 2.8 and 1,680 nM at the A 2A an A 1 ARs, respectively, showed good oral activity at 3 mg/kg in a rat catalepsy model. [11] However, these analogs were found to be associated with the blockade of the hERG (human Ethera-go-go Related Gene) channel, which is related to an augmented risk of cardiac arrhythmia. The basic nitrogen in the side chain at the 7 position was identified as responsible for the inhibition of the hERG channel, thus several derivatives bearing the piperazino moiety directly attached to the phenyl ring were prepared. All the synthesized compounds showed affinity in nanomolar or sub-nanomolar range with a low hERG inhibition. The most potent compound of the series has been the homologue of compound 176 (compound 177). [12] Neustadt et al. investigated also the 2 position of the TP nucleus, by replacing the furyl group, which is a common structural feature of almost all A 2A AR antagonists. Interestingly, 3-cyano-phenyl group maintains affinity and receptor selectivity (178, hA 2A AR K i = 0.7 nM, A 1 /A 2A = 1,071), but failed to show pronounced in vivo activity. [13] Kiowa Hakko Kogyo Co. designed several 7-carbamoyl derivatives of TPs and these compounds were found to be less potent than their corresponding amino derivatives, as an isopropyl (compound 180) gave potent A 2A AR antagonists. [71] In addition, some 8-substituted derivatives were developed in this series, revealing that small a alkylamido group confers high potency at the A 2A AR even when present at the 8 position, such as in the 8-(Nethyl)amido derivative 181, which displaced 96% of a specific radioligand for the A 2A AR at a concentration of 0.1 µM. [71] Recently, a novel series of TP substituted at both the 5 and 8 position was developed and the derivatives were characterized at all the AR subtypes. [14] The introduction of an arylureido moiety at the 5 position (182) gave different results in terms of affinity and selectivity depending on the substitutions at the 8 position. The simultaneous presence at the 8 position of an ethoxycarbonyl (182) or a methyl carboxamido function led to compounds with quite good affinity and selectivity for the hA 2A AR (e.g., compound 182: hA 2A AR K i = 4.82 nM; hA 2A /hA 3 = 0.01; hA 1 /hA 2A = 66.8), whereas a bigger β-phenethylcarboxamido group or the replacement of arylureido group with a phenylacetamido group produced a decrease of affinity at the hA 2A AR. A very different behavior was observed when alkylamino moieties were introduced at the 5 position of 8-ethoxycarbonyl-TP.
In fact, a clear enhancement of affinity at the hA 3 AR was observed for these compounds. Benzylamino moieties led to derivatives displaying good affinity at the hA 3 AR but selectivity is still poor (e.g. compound 183, hA 3 AR K i = 10 nM; hA 1 /hA 3 = 94; hA 2A /hA 3 = 3.2). Better results in terms of both affinity and selectivity at the hA 3 AR were obtained with small alkyl groups at the 5 position, such as for methylamino derivative (184) which showed a K i value of 4.14 nM at the hA 3 AR and was 236-and 25-fold selective against A 1 and A 2A ARs, respectively. [14] The structure activity relationship of TP derivatives is summarized in Figure 14 .
PYRAZOLO[3,4-d]PYRIMIDINES
Over the years, several research groups have been interested in the development of pyrazolo [ can easily be attributed to the fact that PPs (4) are structurally very similar to the purine nucleus (185), whereas the imidazole ring is replaced by a pyrazole ring. In addition, the potent tricyclic adenosine receptor antagonists PTPs (1) are PP-fused derivatives, so PPs (4) can be considered as a structural simplification of this scaffold. (Figure 15) 
Chemistry
The most used starting materials for the synthesis of PPs are the 1-substituted-5-amino-1H-pyrazole-4-carbonitriles (7) or their corresponding regioisomers 3-amino-1-substituted-1H-pyrazole-4-carbonitrile (17) .
These compounds were obtained as discussed in Section 2.1 and their principal applications for the synthesis of PPs were shown in Scheme 18. The 4,6-dichloro-1-substituted-1H-pyrazolo [3,4-d] pyrimidine (188) could be easily obtained by treatment of the corresponding di-hydroxy derivative (187) with phenylphosphoryl dichloride. Compound 187 was obtained by heating the 5-amino-1-substituted-1H-pyrazole-4-carboxamide (186) with urea. The carboxamido group of compound 186 originated from the conversion of the cyano group of compound 7 in acidic conditions. [18, 79] Alternatively, the reaction between compound 7 and potassium ethyl xanthogenate afforded the 4,6-dithiol-PP (189), which thiol groups could be successively alkylated (compounds 190 and 191) . If the alkylation at the 4 position was performed using methyliodide, the resulting methylthio derivative could be used to introduce different amino moieties at the 4 position of the PP scaffold (compound 192). [17, 80] Finally, compound 7, by treatment with an alkyl-or aryl-isocyanate in the presence of a base, such as sodium methoxide or n-butyllithium, led to 5-substitutedpyrazolo [3,4- PP derivatives were developed also starting from 6-amino-4-chloro-PP (30) the synthesis of which is described in Section 2.1 (Scheme 4). Because compound 30 is unsubstituted on the pyrazole ring, the Stille reaction was made on the N-Boc protected derivative and the resulting compound was deprotected by hot dimethylamine. These reactions afforded compounds of general formula 199, which are functionalized on the pyrazole ring by alkylation or by reaction with the appropriated isocyanate, leading to compounds 200 and 201. Alternatively, alkylation on the pyrazole ring could be performed on compound 30 and, then, the aryl moiety introduced by Suzuki or Negishi coupling as shown in Scheme 20. The alkylation step afforded a mixture of N1 and N2 alkylated PP derivatives (202-203), which was used in the next step without purification, affording a mixture of compounds 204 and 205. [18, 79] Venkatesan et al. reported a synthetic approach to obtain directly compounds of general formula 203, starting from the appropriated 3-amino-1-substituted-1H-pyrazole-4-carbonitrile (17) . [20, 21] As displayed in Scheme 21, the Scheme 18. Reagents: i: H 2 SO 4 (aq) , 60°C, 1h, R= CH 2 CH 2 Ph; ii: urea, neat, 180°C, 1h, R= CH 2 CH 2 Ph; iii: PhPOCl 2 , 165°C, 16h, R= CH 2 CH 2 Ph; iv: Potassium ethyl xanthogenate, R = Ph; v: R 1 Br, pyr, rt, R = Ph, R 1 = CH(alkyl)CONH 2 ; vi: R 2 I, NaOH(aq), rt, R = Ph, R 1 = CH(alkyl)CONH 2 , R 2 = CH 3 ; vii: NH 2 R 4 , EtOH, 110°C, sealed tube, 72h. R = Ph, R 1 = CH(alkyl)CONH 2 , R 4 = H, CH 3 ; viii: R 3 NCO, DMF, 80°C, 24h, R = alkyl or aryl, R 3 = CH 3 ; ix: 30% NH 4 OH, DMF, rt, 24h; x: (method A) R 3 NCO, NaOCH 3 , DMF, 60°C, 12h or (method B) n-BuLi, THF, -70°C, R 3 NCO, 1h, -70°C rt, 1h, R = alkyl or aryl, R 3 =alkyl or Ph. hydrolyzed to 4-carboxamido-PP (213), using aqueous hydrogen peroxide and aqueous potassium carbonate, and then it was esterified to obtain the corresponding 4-carboxylate-PP (214). Both compounds 203 and 214 were successively acylated at the free amino group at position 6 of the PP nucleus, by using the desired acylchlorides in the presence of a base (211, 215). [20, 21] Taliani et al. reported a series of 2-substituted-PP as A 3 AR antagonists. [19] As shown in Scheme 22, they used a very simple synthetic approach. In a work aimed to develop conformationally restrained (phenylisopropyl)amino-substituted-PPs, Peet and coworkers explored the effect of substituents at the 4 and 6 position of the PP scaffold. [16] In particular, they observed that compound 231, which is a PP-4,6-dione, showed an IC 50 of 33 μM at the rA 1 AR, whereas the alkylation at the 6 position (concomitantly to the removal of substituent at N7-position) improved the affinity, such as for compound 232 that displayed an about 7-fold increased affinity at the rA 1 AR (IC 50 = 4.8 μM). Interestingly, compound 233, which bears a second substitution at the 4 position with an amino moiety, showed a greater affinity at the A 1 AR subtype than compounds 231 and 232 (Figure 16 ). Instead, Harden and coworkers performed a preliminary investigation on N1-and N5-substituted PPs. The series involved the variation of the substituent at the N1-position with small alkyl groups, phenyl or substituted phenyl moieties (e.g. halogen, NO 2 and NH 2 at m, o and p positions of the phenyl ring), and the variation of the substituent at the N5-position with small alkyl moieties or phenyl group.
Binding data at the A 1 AR demonstrated that compounds possessing substituted aromatic groups showed greater affinity than those with alkyl groups at the N1-position. Additionally, the investigation on the substituted phenyl moieties showed that chlorine produced a greater response than bromine and fluorine substitutions, whereas nitro or amine substitutions were inactive at a concentration of 20 μM. Secondly, substitution of the aromatic group in the meta position gave better affinity values at the rA 1 AR (e.g. compound 234, displ. at 20 μM = 53%, IC 50 = 16.5 μM) than orto or para substitutions (e.g. compound 235, displ. at 20 μM = 7%). In regard to substitutions at the 5 position, an alkyl moiety showed greater AR affinity than the aromatic group. The most active compound of the series was compound 236 which displayed an IC 50 of 9.6 μM. Even though an improvement of affinity was achieved, both affinity and selectivity of these compounds were poor.
In 1984, Davies et al. developed a series of PPs as purinergic receptor antagonists, in particular, as A 1 AR antagonists. [82] The lead compound, 2,2'-((1-phenyl-1H-pyrazolo [3,4-d] pyrimidine-4,6-diyl)bis(sulfanediyl))dipropanamide (237), showed an affinity of 370 nM at the A 1 AR. Compound 237 represented the starting point to perform a structural optimization with the aim to improve binding affinity at the A 1 AR. [17] In fact, compound 237 was modified at the 4 position with mercapto, methylthio, and amino groups in order to investigate the hydrogen-bonding and steric tolerance at this position. At the 6 position of the PP scaffold, the 2-mercaptoalkylamide chain was maintained but varying the length of the alkyl chain. [17] From the binding data at rA 1 AR, it was found that the K i value depended principally on the substituent present at the 4 position and decreased in the order SH>>SCH 3 >NH 2 ≥NHCH 3 , with compound 238 being the most potent of the series at the rA 1 AR (rA 1 AR Ki = 0.745 nM). Moreover, alkyl chain at α position of the sulfur atom at the 6 position of PP was found to influence affinity at the A 1 AR. In this case, K i value decreased in the order iPr>>Et>Pr>Bu, thus indicating that a branched alkyl moiety was unfavorable in terms of affinity, probably due to its steric hindrance. Compounds were tested also at the rA 2A AR and binding data suggests that 4-methylthyio compounds were the most promising compounds because they showed nanomolar affinity at the rA 1 AR, with high levels of selectivity over rA 2A AR (e.g. compound 239, rA 1 AR K i = 6.81 nM, rA 2A /rA 1 > 5,900). [17] A 2A AR antagonists PPs were explored by Gillespie and collaborators as A 2A AR antagonists [18, 79] for their evaluation in the treatment of PD. The 4-(furan-2-yl)PP (240) was found to possess a K i of 48 nM at the hA 2A AR and was 13-fold selective over A 1 AR subtype. (Figure 17 AR K i = 1 nM) of phenyl ring was preferred to ortho-and para-substitutions (e.g. compound 243, hA 2A AR K i = 9 nM), which generally decreased affinity compared to parent compound 241. Finally, furyl moiety at the 4 position of PP was replaced by other aromatic rings, but all the compounds displayed a reduced affinity at the A 2A AR, such as 4-pyrazol-3-yl compound 244 (hA 2A AR K i = 16 nM). [18, 79] A 3 
AR antagonists
The first report on development of A 3 AR antagonists with a PP nucleus came from Arnold and its coworkers, which focused on a series of pyrazolo [3,4- developed a new series of PP based on their previous results on imidazole [ (248) showed higher affinity at the hA 3 AR subtype. For this reason new PP derivatives were synthesized in order to explore the SAR of these compounds at the hA 3 AR. Binding affinity results suggested that phenyl ring at the 6 position was a key feature for recognition at the ARs, since its removal (e.g. compound 249, hA 3 AR K i > 1,000 nM) led to poor affinity to all the ARs. At the 2 position, both methyl and benzyl groups are tolerated, while a phenylethyl moiety decreased affinity at the hA 3 AR. Interestingly, compounds bearing a free amino moiety at the 4 position are poorly active at the hA 3 AR and also totally unselective over the other AR subtypes, while the substitution at the 4 position with arylamides or arylureas enhanced both affinity and selectivity at the hA 3 AR. The best compound of the series is compound 250, which showed a hA 3 Ki value of 0.18 nM. Figure 18 . PP derivatives as A 3 AR antagonists.
Compounds 248 and 250 were subsequently tested on human glioma U87MG cells, and they were able to counteract the proliferation of glioma cells mediated by A 3 AR agonists. [19] Recently, Venkatesan et al. developed a series of 4-chloro-PP as a simplification of the PTP scaffold, which was well-known to afford potent hA 3 AR antagonists (see Section 2.2). [20] The series investigated both 1 and 6 positions of the PP nucleus. Compounds were active in the micromolar range at the hA 3 AR and almost all are completely unselective. On the contrary, when the chloro moiety at the 4 position was substituted with ethyl carboxylate group, an improvement of affinity and especially of selectivity was observed, as clearly shown in Figure 18 for compound 251 (hA 3 AR K i = 900 nM, A 1 /A 3 = 111, A 2A /A 3 = 111). [20] A further investigation on these new compounds revealed that neopentyl moiety at the 2 position is preferred over other alkyl of arylalkyl goups. In addition, replacement of the benzoyl group with a phenylacetyl moiety led to a complete loss of selectivity (252). [21] Figure 19 depicts the SAR analysis of PP compounds at ARs.
MOLECULAR MODELING STUDIES AT THE ADENOSINE RECEPTORS

Homology Modelling
Very recently, several X-ray structures of the hA 2A AR in complex with agonists and antagonists have become available. [83] [84] [85] [86] [87] [88] [89] [90] These structures represent valuable starting points for structure-based drug design approaches.
[91] Moreover, they can serve as templates to gather structural information on the other ARs subtypes by means of homology modelling. The success of the homology modelling approach depends upon at least two key factors: the sequence identity and the sequence alignment between the template and the target structure. In the homology modeling of ARs, the sequence alignment is guided by the Figure  20) . As far as the sequence identity is concerned, the hA 2A AR shares 55.9%, 67.4%, and 47.7% sequence identity with the hA 1 AR, the hA 2B AR, and the hA 3 AR, respectively.
The growing interest in the modeling of GPCRs has prompted the scientific community to release several ad hoc web services [94] [95] [96] [97] [98] among which "Adenosiland", a platform entirely dedicated to ARs. [99] In Adenosiland, homology models for all the cloned ARs are freely available. These models were derived from a homology modeling protocol followed by 20 ns of molecular dynamics (MD) simulations in near-native environment (solvated lipid bilayer embedded receptor). The so refined structures represent a structural alternative to homology models. A tool to guide the user in the selection of an appropriate template to build ARs homology model has also been implemented. [100] The models deposited in Adenosiland as well as the template searching facility have been exploited to gather macromolecular starting points for the rationalization of SARs of different series of ARs antagonists, such as PTP and TP. [14, 42] 
Docking
Provided that a three-dimensional structure -either from experimental data or computationally derived -is available, molecular docking is one of the most widely used structure based drug design techniques. The analysis of docking poses represents a helpful tool to rationalize SARs. With respect to ARs binders, docking studies have been extensively used to elucidate the molecular signatures favoring or affecting the binding of antagonists at the hA 2A and the hA 3 ARs. In some cases, docking studies helped in explaining the selectivity profiles exhibited by the most promising synthetized derivatives. Moreover, the analysis of the docking results allows to speculate on the most favorable orientations of the substituents on the scaffolds, thus providing rationale suggestions for further derivatizations.
With regard to this, we have recently reported on the analysis of the 5 position of the PTP scaffold at the hA 3 AR. [42] In particular, we have evidenced the possibility of the scaffold to adopt two different orientations in the binding site according to the nature of the substituent linked to the N5 atom that gives rise to the interaction with different TM domains ( Figure 21 ). Compounds bearing small alkyl and cycloalkyl groups and polar chains prefer a binding mode (BM1, vertical arrow) that exposes the substituent to the extracellular side and envisages the interaction with TM6, TM7, and EL2 (extracellular loop 2). Ligands bearing aromatic rings, bulky substituents as well as those with the double substitution at the N5 atom, preferentially adopt a binding mode (BM2, horizontal arrow) that points the Readopted from ref [42] . substituent inside the binding cavity interacting with TM2, TM3, and EL2.
The possibility for a scaffold to adopt different binding modes depending on the nature and the steric hindrance of the substituents has also emerged through the analysis of the docking poses at the hA 3 AR of a series of 5,8 disubstituted-TP. (Figure 22 ) [14] Derivatives bearing small alkyl and cycloalkyl groups interact with Asn250 (6.55) through the ethoxycarbonyl group at the 8 position, by pointing the furan ring toward TM2 and exposing the alkyl group to the solvent. Compounds bearing branched chains and benzyl groups interact with Ans250 (6.55) with the N4 of the triazole ring, with the furan ring solvent exposed and the alkyl/benzyl group projected toward TM2.
Molecular Dynamics
Besides molecular docking, MD is a powerful tool nowadays largely used in medicinal chemistry and drug discovery. [101] With respect to the static analysis proposed by the docking solutions, MD simulations enable to take into account also the flexibility of protein side chains and the interactions mediated by water molecules. The description of these two fundamental aspects in ligand binding is still challenging to be depicted by conventional docking approaches. [102] A strategy to follow the dynamics of ligand-receptor interaction is to compute the so-called the "dynamic scoring function" (DSF), [103] i.e. the cumulative sum of electrostatic and hydrophobic contributions to the interaction energy computed between the ligand and selected residues surrounding the binding site over time. This feature has been introduced and exploited to support an apparently less plausible binding mode of a series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo [1,5-c] pyrimidines at the hA 3 AR. [42] In particular, the two different binding modes described above (Figure 20 ) have been validated through 60 ns of membrane MD simulations.
CONCLUSIONS
Adenosine receptor antagonists could be useful for the treatment of hypertension, heart and kidney failure, inflammation, neurodegenerative disorders (e.g. PD), asthma, COPD, cancer and glaucoma, depending on the targeted AR subtype. Therefore, the development of antagonists potent and selective for a specific AR subtype is of remarkable importance. PTP represent one of the most important scaffolds among adenosine receptor antagonists. Synthesis of the PTP scaffold was optimized over the years, allowing the development of extended series of derivatives which led to acquisition of a good SAR profile, especially towards the A 2A and A 3 AR subtypes. Preladenant (2) is a promising PTP derivative that reached phase III clinical trials for the treatment of PD. Unfortunately it failed at this stage of clinical research but the reasons are still unclear. Nevertheless, PTP derivatives are tricyclic compounds with a high molecular weight which exhibit limitations such as poor aqueous solubility and difficult synthetic preparation. TP and PP are bicyclic scaffolds which could be considered as simplified analogs of PTP, possessing a lower molecular weight and thus probably showing better drug-like properties than PTP. TPs were principally developed by industries to obtain A 2A AR antagonists. SAR of these compounds was not fully explored, thus, further investigations on this scaffold are needed. Instead, PPs were studied almost exclusively by academia, which apply very different approaches to find potent AR antagonists. The high structural variability of these compounds and the different biological assays used in the various studies, make difficult to obtain a good SAR profile of these derivatives. Molecular modeling studies helped to rationalize the obtained experimental binding data and also to design new optimized derivatives. Both docking and molecular dynamics are powerful tools largely used in medicinal chemistry and drug discovery. Indeed, optimization of the PTP derivatives, and recently also optimization of the TP and PP derivatives, as AR antagonists were strongly supported by molecular modeling studies. TST, tail suspension test.
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